RPL17 and neoplasm: Monoclonal antibody inhibitors of the programmed death (ligand) 1 (PD- 1/PD-L1) axis play a prominent role in the treatment of many solid tumors and act by reversing the blockage of T cell function, such that tumor-reactive T cells can proceed with tumor cell suppression and killing [1].